Grace Therapeutics, Inc.
GRCE
$3.17
$0.061.83%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 2.14M | 1.55M | 1.51M | 1.86M | 2.26M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 3.09M | 3.18M | 3.70M | 4.83M | 4.96M |
Operating Income | -3.09M | -3.18M | -3.70M | -4.83M | -4.96M |
Income Before Tax | -3.36M | -382.00K | -4.76M | -4.28M | -3.34M |
Income Tax Expenses | -- | -1.02M | -605.00K | -852.00K | -724.00K |
Earnings from Continuing Operations | -3.36M | 636.00K | -4.16M | -3.43M | -2.62M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -3.36M | 636.00K | -4.16M | -3.43M | -2.62M |
EBIT | -3.09M | -3.18M | -3.70M | -4.83M | -4.96M |
EBITDA | -3.09M | -3.18M | -3.70M | -4.83M | -4.96M |
EPS Basic | -0.21 | 0.05 | -0.36 | -0.30 | -0.24 |
Normalized Basic EPS | -0.13 | -0.02 | -0.26 | -0.23 | -0.19 |
EPS Diluted | -0.21 | 0.05 | -0.36 | -0.30 | -0.24 |
Normalized Diluted EPS | -0.13 | -0.02 | -0.26 | -0.23 | -0.19 |
Average Basic Shares Outstanding | 15.92M | 13.83M | 11.51M | 11.51M | 10.93M |
Average Diluted Shares Outstanding | 15.92M | 13.83M | 11.51M | 11.51M | 10.93M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |